EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
Supplementary Data
Supplementary Data
Files in this Data Supplement:
Supplementary Data
- Docx file
Supplementary Table 1
- docx file
Supplementary Table 2
- docx file
Supplementary Table 3
- docx file
Supplementary Table 4
- docx file